-- Curium's Investigational New Drug (IND) application for 177Lu-PSMA-I&T, a therapeutic agent for patients with metastatic castration-resistant prostate cancer (mCRPC), has been accepted by the ...

The FDA has granted traditional approval to Rubraca (rucaparib) for metastatic castration-resistant prostate cancer.

The U.S. Food and Drug Administration (FDA) approved six new therapies in December 2025 for blood cancers, prostate cancer, ...

Rucaparib received FDA approval for BRCA-mutated mCRPC after prior androgen receptor–directed therapy, based on the TRITON3 trial results. The trial demonstrated significant improvement in ...

ECOG performance status is an important risk factor for early mortality in metastatic castration-resistant prostate cancer (mCRPC). Patients with metastatic castration-resistant prostate cancer (mCRPC ...

The term metastatic castration-resistant prostate cancer (mCRPC) refers to a cancer that has spread (metastasized) beyond your prostate gland and for which hormone therapy is no longer effective in ...

Enhanced antitumor activity was seen with the addition of the PARP inhibitor olaparib to the radioligand lutetium Lu 177 vipivotide tetraxetan in patients with metastatic castration-resistant prostate ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window SAN FRANCISCO -- ...

An overview of metastatic castration-resistant prostate cancer (mCRPC) and the role of PSMA in mCRPC. Alicia Morgans, MD: Welcome to the CURE Connections® program on radiopharmaceutical PSMA [prostate ...

Purpose-built facility secures Convergent's drug product manufacturing at the scale needed to meet late-stage CONV01- clinical studies and commercial demand Expanded partnership designed to drive ...